ClinicalTrials.gov
ClinicalTrials.gov Menu

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01822509
Recruitment Status : Active, not recruiting
First Posted : April 2, 2013
Last Update Posted : November 12, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)